255 related articles for article (PubMed ID: 35779497)
21. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.
Willis L; Hayes D; Mansour HM
Lung; 2012 Jun; 190(3):251-62. PubMed ID: 22274758
[TBL] [Abstract][Full Text] [Related]
22. Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.
Stewart IE; Lukka PB; Liu J; Meibohm B; Gonzalez-Juarrero M; Braunstein MS; Lee RE; Hickey AJ
Pharm Res; 2019 Jul; 36(9):136. PubMed ID: 31321552
[TBL] [Abstract][Full Text] [Related]
23. Patient Inspiratory Maneuver Performance; Peak Lungpower, Acceleration and Volume.
Haikarainen J; Vahteristo M; Lähelmä S; Vartiainen V; Malmberg LP
J Aerosol Med Pulm Drug Deliv; 2020 Dec; 33(6):305-313. PubMed ID: 32423277
[No Abstract] [Full Text] [Related]
24. Dry Powder Inhalers: A Focus on Advancements in Novel Drug Delivery Systems.
Mehta P
J Drug Deliv; 2016; 2016():8290963. PubMed ID: 27867663
[TBL] [Abstract][Full Text] [Related]
25. Dry powder inhalers for optimal drug delivery.
Newman SP
Expert Opin Biol Ther; 2004 Jan; 4(1):23-33. PubMed ID: 14680466
[TBL] [Abstract][Full Text] [Related]
26. Evaluating dry powder inhalers: From in vitro studies to mobile health technologies.
Ari A; Alhamad BR
Respir Med; 2023; 215():107281. PubMed ID: 37244487
[TBL] [Abstract][Full Text] [Related]
27. Formulation techniques for high dose dry powders.
Brunaugh AD; Smyth HDC
Int J Pharm; 2018 Aug; 547(1-2):489-498. PubMed ID: 29778822
[TBL] [Abstract][Full Text] [Related]
28. Pulmonary drug delivery systems for tuberculosis treatment.
Pham DD; Fattal E; Tsapis N
Int J Pharm; 2015 Jan; 478(2):517-29. PubMed ID: 25499020
[TBL] [Abstract][Full Text] [Related]
29. Inhalable Nanoparticle-based Dry Powder Formulations for Respiratory Diseases: Challenges and Strategies for Translational Research.
Chan HW; Chow S; Zhang X; Zhao Y; Tong HHY; Chow SF
AAPS PharmSciTech; 2023 Apr; 24(4):98. PubMed ID: 37016029
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
[TBL] [Abstract][Full Text] [Related]
31. Design of dry powder inhalers to improve patient outcomes: it's not just about the device.
Weers JG
Expert Opin Drug Deliv; 2024 Mar; 21(3):365-380. PubMed ID: 38630860
[TBL] [Abstract][Full Text] [Related]
32. Dry powder inhalation: past, present and future.
de Boer AH; Hagedoorn P; Hoppentocht M; Buttini F; Grasmeijer F; Frijlink HW
Expert Opin Drug Deliv; 2017 Apr; 14(4):499-512. PubMed ID: 27534768
[TBL] [Abstract][Full Text] [Related]
33. In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment.
Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
Eur J Pharm Biopharm; 2016 Oct; 107():205-14. PubMed ID: 27422209
[TBL] [Abstract][Full Text] [Related]
34. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G
Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137
[TBL] [Abstract][Full Text] [Related]
35. Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis.
Hickey AJ; Misra A; Fourie PB
J Pharm Sci; 2013 Nov; 102(11):3900-7. PubMed ID: 23963705
[TBL] [Abstract][Full Text] [Related]
36. Active pulmonary targeting against tuberculosis (TB) via triple-encapsulation of Q203, bedaquiline and superparamagnetic iron oxides (SPIOs) in nanoparticle aggregates.
Poh W; Ab Rahman N; Ostrovski Y; Sznitman J; Pethe K; Loo SCJ
Drug Deliv; 2019 Dec; 26(1):1039-1048. PubMed ID: 31691600
[TBL] [Abstract][Full Text] [Related]
37. Cepharanthine Dry Powder Inhaler for the Treatment of Acute Lung Injury.
Liang D; Wang W; Chen G; Li J; Dou G; Gan H; Han P; Du L; Gu R
Molecules; 2023 May; 28(11):. PubMed ID: 37298919
[TBL] [Abstract][Full Text] [Related]
38. Devices for dry powder drug delivery to the lung.
Berkenfeld K; Lamprecht A; McConville JT
AAPS PharmSciTech; 2015 Jun; 16(3):479-90. PubMed ID: 25964142
[TBL] [Abstract][Full Text] [Related]
39. Pressurised metered-dose inhalers (MDIs) versus dry powder inhalers devices (DPIs) to rapid-acting inhaled b2-agonists for asthma in children.
Negro Alvarez JM; Miralles López JC; Félix Toledo R; Pagán Alemán JA; García Sellés FJ; López Sánchez JD; Hernández García J
Allergol Immunopathol (Madr); 2002; 30(4):245-9. PubMed ID: 12199971
[TBL] [Abstract][Full Text] [Related]
40. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
